<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974571</url>
  </required_header>
  <id_info>
    <org_study_id>0476-246</org_study_id>
    <secondary_id>MK0476-246</secondary_id>
    <secondary_id>2009_659</secondary_id>
    <nct_id>NCT00974571</nct_id>
  </id_info>
  <brief_title>Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study will assess the ability of montelukast to improve the signs and symptoms of
      perennial allergic rhinitis compared to placebo. Cetirizine is included in the study as an
      active control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">May 2002</completion_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Daytime Nasal Symptoms Score</measure>
    <time_frame>Baseline and first 4 weeks of a 6-week treatment period</time_frame>
    <description>Mean change from baseline in Daytime Nasal Symptoms score.
Patients were asked to rate each nasal symptom of Congestion, Rhinorrhea, Itching, and Sneezing daily on a 4-point scale [Score 0 (best) to 3 (worst)]. The average of the 4 individual nasal symptoms scores was reported as the Daytime Nasal Symptoms Score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Nighttime Symptoms Score</measure>
    <time_frame>Baseline and first 4 weeks in 6-week treatment period</time_frame>
    <description>Mean change from baseline in Nighttime Symptoms Score.
Patients were asked to rate each symptom daily on a 4-point scale [Score 0 (best) to 3 (worst)], and the average score of Nasal Congestion Upon Awakening, Difficulty Going to Sleep, and Nighttime Awakenings was reported as the Nighttime Symptoms Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Composite Symptoms Score</measure>
    <time_frame>Baseline and first 4 weeks in 6-week treatment period</time_frame>
    <description>Composite Symptoms Scores were computed as the average of the Daytime Nasal Symptoms Scores [Score 0 (best) to 3 (worst)]. and Nighttime Symptoms Scores collected [Score 0 (best) to 3 (worst)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Evaluation of Allergic Rhinitis</measure>
    <time_frame>End of the first 4 weeks in 6-week treatment period</time_frame>
    <description>An evaluation by the patient, administered at week 4 of the study (or upon discontinuation) using a 7-point scale [Score 0 (best) to 6 (worst)], of the change in symptoms as compared to the beginning of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation of Allergic Rhinitis</measure>
    <time_frame>End of the first 4 weeks in 6-week treatment period</time_frame>
    <description>An evaluation by the physician, administered at week 4 of the study (or upon discontinuation) using a 7-point scale [Score 0 (best) to 6 (worst)], of the change in symptoms as compared to the beginning of the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1365</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cetirizine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast sodium</intervention_name>
    <description>montelukast 10 mg tablet orally once daily at bedtime for 6 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: cetirizine</intervention_name>
    <description>cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo</intervention_name>
    <description>placebo tablet orally once daily at bedtime for 6 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a documented clinical history of perennial allergic rhinitis

          -  Patient is a nonsmoker

          -  Patient is in good general health

        Exclusion Criteria:

          -  Patient is hospitalized

          -  Patient is a woman who is &lt;8 weeks postpartum or is breast-feeding

          -  Patient is a current or past abuser of alcohol or illicit drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Philip G, Williams-Herman D, Patel P, Weinstein SF, Alon A, Gilles L, Tozzi CA, Dass SB, Reiss TF. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc. 2007 May-Jun;28(3):296-304.</citation>
    <PMID>17619558</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <results_first_submitted>September 17, 2009</results_first_submitted>
  <results_first_submitted_qc>May 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2010</results_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>74 study sites in the United States
Primary Therapy: Nov-2001 to May-2002</recruitment_details>
      <pre_assignment_details>Patients who required excluded medication and those who did not meet a minimum predefined level of combined daytime rhinitis symptoms score during the run-in period were excluded from randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Montelukast 10 mg</title>
          <description>Montelukast 10-mg film-coated tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Cetirizine 10 mg</title>
          <description>Montelukast matching-image placebo tablet and cetirizine 10-mg tablet orally once daily at bedtime for 6 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Montelukast matching-image placebo tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="630"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="613"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="562"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="530"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Montelukast 10 mg</title>
          <description>Montelukast 10-mg film-coated tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Cetirizine 10 mg</title>
          <description>Montelukast matching-image placebo tablet and cetirizine 10-mg tablet orally once daily at bedtime for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Montelukast matching-image placebo tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="630"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="613"/>
            <count group_id="B4" value="1365"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="12.87"/>
                    <measurement group_id="B2" value="36.3" spread="13.67"/>
                    <measurement group_id="B3" value="35.3" spread="13.17"/>
                    <measurement group_id="B4" value="35.4" spread="13.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="419"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="418"/>
                    <measurement group_id="B4" value="922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Composite Symptoms score</title>
          <description>Composite Symptoms Scores were computed as the average of the Daytime Nasal Symptoms Scores [Score 0 (best) to 3 (worst)] and Nighttime Symptoms Scores [Score 0 (best) to 3 (worst)].</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.86" spread="0.44"/>
                    <measurement group_id="B2" value="1.89" spread="0.43"/>
                    <measurement group_id="B3" value="1.82" spread="0.45"/>
                    <measurement group_id="B4" value="1.85" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daytime Nasal Symptoms score</title>
          <description>Patients were asked to rate each of 4 nasal symptoms of Congestion, Rhinorrhea, Itching, and Sneezing daily on a 4-point scale [Score 0 (best) to 3 (worst)]. The average of the 4 individual nasal symptom scores was reported as the Daytime Nasal Symptoms Score.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.08" spread="0.40"/>
                    <measurement group_id="B2" value="2.13" spread="0.37"/>
                    <measurement group_id="B3" value="2.07" spread="0.40"/>
                    <measurement group_id="B4" value="2.08" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nighttime Symptoms score</title>
          <description>Patients were asked to rate each of 3 symptoms of Nasal Congestion Upon Awakening, Difficulty Going to Sleep, and Nighttime Awakenings daily on a 4-point scale [Score 0 (best) to 3 (worst)], and the average score of the 3 symptoms was reported as the Nighttime Symptoms Score.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.63" spread="0.62"/>
                    <measurement group_id="B2" value="1.65" spread="0.61"/>
                    <measurement group_id="B3" value="1.58" spread="0.62"/>
                    <measurement group_id="B4" value="1.61" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Daytime Nasal Symptoms Score</title>
        <description>Mean change from baseline in Daytime Nasal Symptoms score.
Patients were asked to rate each nasal symptom of Congestion, Rhinorrhea, Itching, and Sneezing daily on a 4-point scale [Score 0 (best) to 3 (worst)]. The average of the 4 individual nasal symptoms scores was reported as the Daytime Nasal Symptoms Score.</description>
        <time_frame>Baseline and first 4 weeks of a 6-week treatment period</time_frame>
        <population>All patients who had a baseline and at least one posttreatment measurement were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 10 mg</title>
            <description>Montelukast 10-mg film-coated tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cetirizine 10 mg</title>
            <description>Montelukast matching-image placebo tablet and cetirizine 10-mg tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Daytime Nasal Symptoms Score</title>
          <description>Mean change from baseline in Daytime Nasal Symptoms score.
Patients were asked to rate each nasal symptom of Congestion, Rhinorrhea, Itching, and Sneezing daily on a 4-point scale [Score 0 (best) to 3 (worst)]. The average of the 4 individual nasal symptoms scores was reported as the Daytime Nasal Symptoms Score.</description>
          <population>All patients who had a baseline and at least one posttreatment measurement were included.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="626"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="609"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" lower_limit="-0.43" upper_limit="-0.36"/>
                    <measurement group_id="O2" value="-0.45" lower_limit="-0.54" upper_limit="-0.37"/>
                    <measurement group_id="O3" value="-0.36" lower_limit="-0.39" upper_limit="-0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Nighttime Symptoms Score</title>
        <description>Mean change from baseline in Nighttime Symptoms Score.
Patients were asked to rate each symptom daily on a 4-point scale [Score 0 (best) to 3 (worst)], and the average score of Nasal Congestion Upon Awakening, Difficulty Going to Sleep, and Nighttime Awakenings was reported as the Nighttime Symptoms Score.</description>
        <time_frame>Baseline and first 4 weeks in 6-week treatment period</time_frame>
        <population>All patients who had a baseline and at least one posttreatment measurement were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 10 mg</title>
            <description>Montelukast 10-mg film-coated tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cetirizine 10 mg</title>
            <description>Montelukast matching-image placebo tablet and cetirizine 10-mg tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Nighttime Symptoms Score</title>
          <description>Mean change from baseline in Nighttime Symptoms Score.
Patients were asked to rate each symptom daily on a 4-point scale [Score 0 (best) to 3 (worst)], and the average score of Nasal Congestion Upon Awakening, Difficulty Going to Sleep, and Nighttime Awakenings was reported as the Nighttime Symptoms Score.</description>
          <population>All patients who had a baseline and at least one posttreatment measurement were included.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="626"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="609"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" lower_limit="-0.32" upper_limit="-0.25"/>
                    <measurement group_id="O2" value="-0.30" lower_limit="-0.38" upper_limit="-0.23"/>
                    <measurement group_id="O3" value="-0.26" lower_limit="-0.29" upper_limit="-0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Composite Symptoms Score</title>
        <description>Composite Symptoms Scores were computed as the average of the Daytime Nasal Symptoms Scores [Score 0 (best) to 3 (worst)]. and Nighttime Symptoms Scores collected [Score 0 (best) to 3 (worst)].</description>
        <time_frame>Baseline and first 4 weeks in 6-week treatment period</time_frame>
        <population>All patients who had a baseline and at least one posttreatment measurement were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 10 mg</title>
            <description>Montelukast 10-mg film-coated tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cetirizine 10 mg</title>
            <description>Montelukast matching-image placebo tablet and cetirizine 10-mg tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Composite Symptoms Score</title>
          <description>Composite Symptoms Scores were computed as the average of the Daytime Nasal Symptoms Scores [Score 0 (best) to 3 (worst)]. and Nighttime Symptoms Scores collected [Score 0 (best) to 3 (worst)].</description>
          <population>All patients who had a baseline and at least one posttreatment measurement were included.</population>
          <units>Score 0 (best) to 3 (worst)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="626"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="609"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" lower_limit="-0.37" upper_limit="-0.31"/>
                    <measurement group_id="O2" value="-0.38" lower_limit="-0.45" upper_limit="-0.31"/>
                    <measurement group_id="O3" value="-0.30" lower_limit="-0.34" upper_limit="-0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Evaluation of Allergic Rhinitis</title>
        <description>An evaluation by the patient, administered at week 4 of the study (or upon discontinuation) using a 7-point scale [Score 0 (best) to 6 (worst)], of the change in symptoms as compared to the beginning of the study.</description>
        <time_frame>End of the first 4 weeks in 6-week treatment period</time_frame>
        <population>The primary efficacy analyses were based on the intention-to-treat (all-patients-treated) principle. Since only 1 measurement was obtained during the treatment period, no missing values were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 10 mg</title>
            <description>Montelukast 10-mg film-coated tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cetirizine 10 mg</title>
            <description>Montelukast matching-image placebo tablet and cetirizine 10-mg tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Evaluation of Allergic Rhinitis</title>
          <description>An evaluation by the patient, administered at week 4 of the study (or upon discontinuation) using a 7-point scale [Score 0 (best) to 6 (worst)], of the change in symptoms as compared to the beginning of the study.</description>
          <population>The primary efficacy analyses were based on the intention-to-treat (all-patients-treated) principle. Since only 1 measurement was obtained during the treatment period, no missing values were imputed.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="617"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" lower_limit="2.11" upper_limit="2.32"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.92" upper_limit="2.38"/>
                    <measurement group_id="O3" value="2.41" lower_limit="2.30" upper_limit="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation of Allergic Rhinitis</title>
        <description>An evaluation by the physician, administered at week 4 of the study (or upon discontinuation) using a 7-point scale [Score 0 (best) to 6 (worst)], of the change in symptoms as compared to the beginning of the study.</description>
        <time_frame>End of the first 4 weeks in 6-week treatment period</time_frame>
        <population>The primary efficacy analyses were based on the intention-to-treat (all-patients-treated) principle. Since only 1 measurement was obtained during the treatment period, no missing values were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 10 mg</title>
            <description>Montelukast 10-mg film-coated tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cetirizine 10 mg</title>
            <description>Montelukast matching-image placebo tablet and cetirizine 10-mg tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation of Allergic Rhinitis</title>
          <description>An evaluation by the physician, administered at week 4 of the study (or upon discontinuation) using a 7-point scale [Score 0 (best) to 6 (worst)], of the change in symptoms as compared to the beginning of the study.</description>
          <population>The primary efficacy analyses were based on the intention-to-treat (all-patients-treated) principle. Since only 1 measurement was obtained during the treatment period, no missing values were imputed.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="603"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" lower_limit="2.16" upper_limit="2.36"/>
                    <measurement group_id="O2" value="2.20" lower_limit="1.99" upper_limit="2.42"/>
                    <measurement group_id="O3" value="2.33" lower_limit="2.23" upper_limit="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 6 week, double-blind treatment period, and up to and including 14 days after the last dose of study therapy</time_frame>
      <desc>The number of patients listed in the Adverse Event tables (613 in the placebo group, 630 in the montelukast group, and 122 in the cetirizine group) is the number of patients who received study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Montelukast 10 mg</title>
          <description>Montelukast 10-mg film-coated tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Cetirizine 10 mg</title>
          <description>Montelukast matching-image placebo tablet and cetirizine 10-mg tablet orally once daily at bedtime for 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Montelukast matching-image placebo tablet and cetirizine matching-image placebo tablet orally once daily at bedtime for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Merck CRISP Dict.</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Unstable Angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Merck CRISP Dict.</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

